BTK inhibitors were developed for the treatment of lymphoproliferative disorders: among them Ibrutinib is already FDA-approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia and Waldenström macroglobulinemia. Here, BTK is linked to B-cell chronic lymphocytic leukemia.